Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning

Blood

Volumn 117, Issue 1, 2011, Pages 316-322

  Majhail, Navneet S ^a   Brazauskas, Ruta ^b   Douglas Rizzo, J ^b   Sobecks, Ronald M ^c   Wang, Zhiwei ^b   Horowitz, Mary M ^b   Bolwell, Brian ^c   Wingard, John R ^d   Socie, Gerard ^e  

^a CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYUREA; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERFERON; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER RISK; CANCER SURVIVAL; CELL THERAPY; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; ESOPHAGUS CANCER; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; MOUTH CAVITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SOFT TISSUE CANCER; SOLID TUMOR; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 78650988748     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-294629     Document Type: Article

References (29)

1. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21(7):1352-1358.
2. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464-471.
3. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stemcell transplantation: an international case-control study. Blood. 2005;105(10):3802-3811.
4. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897-904.
5. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood. 2008;111(2):939-944.
6. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer. 2007;109(1):84-92.
7. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med. 1999;131(10):738-744.
8. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006;24(7):1119-1126.
9. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175-1183.
10. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000;18(2):348-357.
11. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14-21.
12. Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007;25(17):2449-2454.
13. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309-1310.
14. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006;12(8):876-884.
15. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N. SEER Cancer Statistics Review, 1975-2006, based on November 2008 SEER data submission. National Cancer Institute. http://seer.cancer.gov/csr/1975-2006/. Accessed August 1, 2010.
16. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents. Vol. IX. Lyon, France: International Agency for Research on Cancer Scientific Publications No. 160; 2007.
17. Breslow NE, Day NE. The design and analysis of cohort studies. In: Statistical Methods in Cancer Research. Vol II. Lyon, France: International Agency for Research on Cancer Scientific Publications No. 82; 1987:48-81.
18. Breslow NE. Elementary methods of cohort analysis. Int J Epidemiol. 1984;13(1):112-115.
19. Preston DL, Lubin JH, Pierce DA. Epicure User's Guide. Seattle, WA: Hirosoft International; 1993.
20. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-202.
21. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94(3):182-192.
22. Savani BN, Goodman S, Barrett AJ. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? Clin Cancer Res. 2009;15(7):2219-2221.
23. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res. 2006;66(16):8026-8036.
24. Tsuruta N, Yatsunami J, Takayama K, Nakanishi Y, Ichinose Y, Hara N. Granulocyte-macrophagecolony stimulating factor stimulates tumor invasiveness in squamous cell lung carcinoma. Cancer. 1998;82(11):2173-2183.
25. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005;5(12):943-955.
26. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol. 2009;27(5):791-798.
27. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351(9097):178-181.
28. Fenske TS, McMahon C, Edwin D, et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 2006;66(10):5029-5038.
29. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12(2):138-151.